Chronic kidney disease

Said, Albara; Desai, Chaitanya; Lerma, Edgar V.

doi:10.1016/j.disamonth.2015.08.001

Cited by 16 publications

(13 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chronic kidney disease-related atherosclerosis (CKD-A) is more complex and is related to traditional and non-traditional risk factors, including inflammation, endothelial dysfunction, oxidative stress, vascular calcification, and volume overload. All of these problems lead to hypertension, anemia, mineral and bone disorders, and vascular remodeling and damage [ 2 ]. However, these risk factors and complications, especially inflammation and endothelial dysfunction, are also related to the pathogenesis of non-renal atherosclerotic CVDs [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Label-Free Quantitative Proteomics Reveals Differences in Molecular Mechanism of Atherosclerosis Related and Non-Related to Chronic Kidney Disease

Łuczak

Suszyńska-Zajczyk

Marczak

et al. 2016

IJMS

View full text Add to dashboard Cite

The major cause of mortality in patients with chronic kidney disease (CKD) is atherosclerosis related to traditional and non-traditional risk factors. However, the understanding of the molecular specificity that distinguishes the risk factors for classical cardiovascular disease (CVD) and CKD-related atherosclerosis (CKD-A) is far from complete. In this study we investigated the disease-related differences in the proteomes of patients with atherosclerosis related and non-related to CKD. Plasma collected from patients in various stages of CKD, CVD patients without symptoms of kidney dysfunction, and healthy volunteers (HVs), were analyzed by a coupled label-free and mass spectrometry approach. Dysregulated proteins were confirmed by an enzyme-linked immunosorbent assay (ELISA). All proteomic data were correlated with kidney disease development and were subjected to bioinformatics analysis. One hundred sixty-two differentially expressed proteins were identified. By directly comparing the plasma proteomes from HVs, CKD, and CVD patients in one study, we demonstrated that proteins involved in inflammation, blood coagulation, oxidative stress, vascular damage, and calcification process exhibited greater alterations in patients with atherosclerosis related with CKD. These data indicate that the above nontraditional risk factors are strongly specific for CKD-A and appear to be less essential for the development of “classical” CVD.

show abstract

Section: Introductionmentioning

confidence: 99%

Label-Free Quantitative Proteomics Reveals Differences in Molecular Mechanism of Atherosclerosis Related and Non-Related to Chronic Kidney Disease

Łuczak

Suszyńska-Zajczyk

Marczak

et al. 2016

IJMS

View full text Add to dashboard Cite

show abstract

“…Nowadays, chronic kidney diseases (CKDs) are the most common forms of kidney disease, with an estimated prevalence of about 10.4% among men and 11.8% among women all around the world (12). All recently published data seem to indicate that the incidence of CKD is rising (11,25) and there are international differences in CKD prevalence (3).…”

Section: Introductionmentioning

confidence: 99%

A brief review on the rising incidence of chronic kidney diseases and non-alcoholic fatty liver disease

Nagy

Kovács

2019

Physiol. Int.

View full text Add to dashboard Cite

Chronic kidney diseases (CKDs) are the most common forms of kidney disease all around the world. The incidence of CKD is rising, which is mainly driven by population aging as well as by a global rise in hypertension, metabolic syndrome, and metabolic risk factors, particularly obesity and type-2 diabetes. The high mortality, morbidity of CKD, and the health care costs of the renal replacement therapy have led investigators to seek recent and potentially modifiable risk factors such as non-alcoholic fatty liver disease (NAFLD). NAFLD is the hepatic manifestation of metabolic syndrome and the most common cause of chronic liver disease. It incorporates a spectrum of liver diseases ranging from simple steatosis to steatohepatitis, liver cirrhosis, and hepatocellular carcinoma. On the basis of recent publications, the prevalence of CKD is significantly increased among patients with NAFLD, and the prevalence of NAFLD is also higher in CKD patients than in patients without NAFLD. These findings suggest that patients with NAFLD should be screened for CKD and patients with CKD and metabolic syndrome should be screened for NAFLD. Patients with NAFLD and CKD should be treated and followed up by a multidisciplinary team that involves specialists in hepatology, nephrology, diabetes, and cardiology.

show abstract

“…Chronic kidney disease (CKD) is increasing worldwide, it has been recognized as a major and independent risk factor for cardiovascular events (CVs) [ 1 – 3 ], such as coronary artery disease (CAD). Patients with CAD were frequently shown to have impaired renal function, which may contribute to worse clinical outcomes.…”

Section: Introductionmentioning

confidence: 99%

Effects of statin therapy on chronic kidney disease patients with coronary artery disease

Shen¹,

Chen²,

Lu³

et al. 2018

Lipids Health Dis

View full text Add to dashboard Cite

BackgroundLong-term persistence of statin therapy provided an ongoing reduction in mortality among patients with and without a known history of CVD, and renoprotective effect on CKD patients. Until now, very few reports are available from China to address the effects of statin therapy in CKD + CAD patients.MethodsWe compared the effects of long-term statin therapy (follow-up time 4 years) in terms of cardiovascular events, all-cause death, and cardiac death among 254 CKD patients with or without CAD.ResultsLong-term statin therapy was much more effective in the CKD + CAD patients compared with CKD patients. In the CAD + CKD patients, long-term statins showed a 22.2% reduction in the CVs rate (P = 0.012). With regard to the all-cause and cardiac deaths, long-term statins had significant treatment effects on the CAD + CKD patients (reduction of about 28.1% in mortality rates, P < 0.001). In contrast, long-term statin therapy exerted no significant influence on the clinical outcomes of the CKD-only patients.ConclusionLong-term statin therapy more dramatically reduced the CVs and mortality rates of the CKD patients with concomitant CAD. In contrast, CKD-only patients had a good prognosis and did not appear to require statin treatment.

show abstract

Chronic kidney disease

Cited by 16 publications

References 9 publications

Label-Free Quantitative Proteomics Reveals Differences in Molecular Mechanism of Atherosclerosis Related and Non-Related to Chronic Kidney Disease

Label-Free Quantitative Proteomics Reveals Differences in Molecular Mechanism of Atherosclerosis Related and Non-Related to Chronic Kidney Disease

A brief review on the rising incidence of chronic kidney diseases and non-alcoholic fatty liver disease

Effects of statin therapy on chronic kidney disease patients with coronary artery disease

Contact Info

Product

Resources

About